欧美成一级-欧美成在人线a免费-欧美传媒影-欧美大逼逼-欧美大成色www永久网站婷-欧美大胆a级视频

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Enhanced T Cell Platforms

Enhanced T Cell Platforms (HyperTCell ®), including HyperCART® , are mainly to solve the global highlighted problem in solid tumor therapy through genetic modification of T cells. HyperCART® takes improving the clinical efficacy of CAR-T in solid tumors as its core purpose. Based on the concept of synthetic biology, HyperCART® adopts efficient gene delivery system to target tumor cells specifically, reverse the immuno suppressive state and improve the predicament of difficult infiltration and poor efficacy of traditional CAR-T in solid tumor therapy. 


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 日本视频在线观看不卡高清免费 | 欧美成人天天综合天天在线 | 欧美日韩一区精品视频一区二区 | 欧美日本国产在线观看精品 | 无码国产玉足脚交久 | 日韩一区二区三区激情 | 少妇一级aa | 午夜剧场 | 精品久久综合1区2区3区激情 | 国产热门视频在线观看日 | 国产精品美女久久久久αv福利 | 人人操人人色 | 综合亚洲日韩精品区 | 最近更新 | 水蜜桃在线观看 | 亚洲欧美成人另类在线观看 | 日韩中文字幕综合久久久 | 精品一区二区日本高清 | 日本乱理伦片中文 | 国产精品99无码一区二蜜桃 | 欧美日韩免 | 国产成人精品三级麻豆 | 欧美蝌蚪窝| 亚洲精品视频在线观看你懂 | 韩剧排行榜 | 午夜成人影视 | 国产精品成人无码视频 | 国产成年 | 国产av无码精品一品二区三区 | 欧美久久国产精品 | 午夜国产精品水蜜桃视频人 | 亚洲欧美丝袜精品久久 | 日本免费综 | 日本熟妇人妻无码av | 欧美日本国产在线观看精品 | 亚洲清纯唯美区一区二 | 午夜亚洲av日韩av无码大全 | 国产三级在线观看专区 | 一级黄色录像视频大片播放 | 亚洲日韩性爱在线 | 黄色电影网 |